FDA clears Roche/Genentech to market Avastin in ovarian cancer

15 Nov 2014

• By Donna Young

Roche and its US subsidiary Genentech were given the go-ahead by the FDA on 14 November to market Avastin (bevacizumab) plus chemotherapy to treat women with platinum-resistant, recurrent ovarian cancer.

FDA clears Roche/Genentech to market Avastin in ovarian cancer

More from Anticancer

More from Therapy Areas